SG11202112252UA - Bnip3 peptides for treatment of reperfusion injury - Google Patents
Bnip3 peptides for treatment of reperfusion injuryInfo
- Publication number
- SG11202112252UA SG11202112252UA SG11202112252UA SG11202112252UA SG11202112252UA SG 11202112252U A SG11202112252U A SG 11202112252UA SG 11202112252U A SG11202112252U A SG 11202112252UA SG 11202112252U A SG11202112252U A SG 11202112252UA SG 11202112252U A SG11202112252U A SG 11202112252UA
- Authority
- SG
- Singapore
- Prior art keywords
- bnip3
- peptides
- treatment
- reperfusion injury
- reperfusion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7019—Ischaemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7038—Hypoxia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19173715 | 2019-05-10 | ||
| PCT/EP2020/062926 WO2020229362A1 (en) | 2019-05-10 | 2020-05-08 | Bnip3 peptides for treatment of reperfusion injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112252UA true SG11202112252UA (en) | 2021-12-30 |
Family
ID=66483874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112252UA SG11202112252UA (en) | 2019-05-10 | 2020-05-08 | Bnip3 peptides for treatment of reperfusion injury |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220220174A1 (en) |
| EP (1) | EP3966230A1 (en) |
| JP (1) | JP2022532092A (en) |
| KR (1) | KR20220007084A (en) |
| CN (1) | CN114026114A (en) |
| AU (1) | AU2020275076A1 (en) |
| BR (1) | BR112021022156A2 (en) |
| CA (1) | CA3138825A1 (en) |
| CO (1) | CO2021015130A2 (en) |
| CU (1) | CU20210092A7 (en) |
| EA (1) | EA202192970A1 (en) |
| IL (1) | IL287946A (en) |
| MX (1) | MX2021013510A (en) |
| SG (1) | SG11202112252UA (en) |
| WO (1) | WO2020229362A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112608972B (en) * | 2020-12-21 | 2021-09-10 | 广东源心再生医学有限公司 | Application of MYOG gene as target in preparation of medicine for treating cardiovascular diseases related to myocardial apoptosis |
| WO2022236258A1 (en) * | 2021-05-04 | 2022-11-10 | Corvitus Gmbh | Method for inhibiting reperfusion injury |
| WO2023079141A2 (en) | 2021-11-05 | 2023-05-11 | Tienush Rassaf | Amelioration and treatment of infarction damage |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2838444B1 (en) * | 2002-04-10 | 2016-01-01 | Neovacs | NEW PEPTIDES AND THEIR THERAPEUTIC APPLICATION |
| WO2004009780A2 (en) * | 2002-07-22 | 2004-01-29 | University Of Miami | Preventing ischemia-induced cell damage |
| EP2072527A1 (en) * | 2007-12-21 | 2009-06-24 | Altonabiotec AG | Fusion polypeptides comprising a SHBG dimerization component and uses thereof |
| US20130196922A1 (en) * | 2010-07-21 | 2013-08-01 | University Of Manitoba | Bnip3 isoforms and methods of use |
-
2020
- 2020-05-08 WO PCT/EP2020/062926 patent/WO2020229362A1/en unknown
- 2020-05-08 CN CN202080044457.6A patent/CN114026114A/en active Pending
- 2020-05-08 BR BR112021022156A patent/BR112021022156A2/en unknown
- 2020-05-08 US US17/608,655 patent/US20220220174A1/en active Pending
- 2020-05-08 KR KR1020217039113A patent/KR20220007084A/en unknown
- 2020-05-08 AU AU2020275076A patent/AU2020275076A1/en active Pending
- 2020-05-08 CU CU2021000092A patent/CU20210092A7/en unknown
- 2020-05-08 SG SG11202112252UA patent/SG11202112252UA/en unknown
- 2020-05-08 EA EA202192970A patent/EA202192970A1/en unknown
- 2020-05-08 CA CA3138825A patent/CA3138825A1/en active Pending
- 2020-05-08 EP EP20724123.3A patent/EP3966230A1/en active Pending
- 2020-05-08 MX MX2021013510A patent/MX2021013510A/en unknown
- 2020-05-08 JP JP2021566026A patent/JP2022532092A/en active Pending
-
2021
- 2021-11-09 CO CONC2021/0015130A patent/CO2021015130A2/en unknown
- 2021-11-09 IL IL287946A patent/IL287946A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2021015130A2 (en) | 2021-11-30 |
| EA202192970A1 (en) | 2022-03-03 |
| MX2021013510A (en) | 2022-02-11 |
| WO2020229362A1 (en) | 2020-11-19 |
| IL287946A (en) | 2022-01-01 |
| CN114026114A (en) | 2022-02-08 |
| AU2020275076A1 (en) | 2021-11-25 |
| US20220220174A1 (en) | 2022-07-14 |
| CU20210092A7 (en) | 2022-06-06 |
| KR20220007084A (en) | 2022-01-18 |
| EP3966230A1 (en) | 2022-03-16 |
| JP2022532092A (en) | 2022-07-13 |
| BR112021022156A2 (en) | 2021-12-21 |
| CA3138825A1 (en) | 2020-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287946A (en) | Bnip3 peptides for treatment of reperfusion injury | |
| IL272336A (en) | Amino acid compositions for the treatment of neuronal injury | |
| SG11202104923YA (en) | Pharmaceutical combination for treatment of cancer | |
| GB201804514D0 (en) | Treatment of pyroptosis | |
| ZA202007055B (en) | Compositions for the treatment of skin conditions | |
| ZA202006610B (en) | Compositions for the treatment of skin conditions | |
| SG11202006374VA (en) | Treatment of demyelinating diseases | |
| IL253854B (en) | Mebendazole polymorph for treatment and prevention of tumors | |
| IL261014A (en) | Aav vectors for treatment of dominant retinitis pigmentosa | |
| FI3645488T3 (en) | Process for the purification of ethylene glycol | |
| GB201902419D0 (en) | Treatment of kidney injury | |
| IL270199A (en) | Peptides for treatment of diabetes | |
| SG11202011117VA (en) | Treatment of cancer | |
| PL3612208T3 (en) | Coversin for the treatment of autoimmune blistering diseases | |
| IL271965A (en) | Neoantigen vaccine composition for treatment of cancer | |
| GB201804515D0 (en) | Treatment of necroptosis | |
| IL283742A (en) | Novel approach for treatment of cancer using immunomodulation | |
| IL282519A (en) | Peptide fragments for treatment of diabetes | |
| GB201714307D0 (en) | Treatment of neurodegenerative diseases | |
| IL263564B (en) | Peptides for the treatment of osteoarthritis | |
| GB201805100D0 (en) | Treatment of sarcopenic diseases | |
| GB201918022D0 (en) | Treatment or prevention of Ischaemic Stroke Reperfusion Injury | |
| GB201907305D0 (en) | Treatment of conditions | |
| GB201714303D0 (en) | Treatment of neurodegenerative diseases | |
| GB201714311D0 (en) | Treatment of neurodegenerative diseases |